Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the <i>ex vivo</i> human cotyledon model
Placental transfer was high for the nucleoside analogue favipiravir, while it was low for molnupiravir and low for the protease inhibitor nirmatrelvir but increased by ritonavir. Clinical data are required to confirm the placental transfer and determine the safety of COVID antivirals in pregnancy.
Authors
- Laurent Mandelbrot (ORCID: https://orcid.org/0000-0002-5883-7597)
- Gilles Peytavin (ORCID: https://orcid.org/0000-0002-4359-537X)
- Solene Labaye
- Fatima Djellali
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Hôpital Louis-Mourier (FR)
- Sorbonne Paris Cité (FR)
- Ecologie & Evolution (FR)
- Hôpital Bichat-Claude-Bernard (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1093/jac/dkaf302
- Primary Topic
- COVID-19 Impact on Reproduction
- Type
- article
- Field-Weighted Citation Impact
- 0.00